[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:myxoid-liposarcoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":43,"states":44},"Myxoid Liposarcoma",5,4,[8,16,23,29,36],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07261657","N-803 in Patients With Progressive Synovial Sarcoma and Myxoid\u002FRound Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy",[12],"Early Phase 1","RECRUITING","2026-08-26T02:19:07.104270Z","2026-07-05T05:32:16.673151Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06644755","First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors",[20],"Phase 1","2026-08-26T02:17:25.718160Z","2026-05-05T02:43:27.064259Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06083883","Phase I\u002FIb Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1",[20],"2026-08-26T02:18:26.129155Z","2026-04-29T02:57:57.066842Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT06239272","NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)",[33],"Phase 1\u002FPhase 2","2026-08-26T02:18:06.247899Z","2026-07-19T19:36:05.068230Z",{"nct_id":37,"title":38,"phases":39,"status":40,"updated_at":41,"content_modified":42},"NCT06748872","EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And\u002For Synovial Sarcoma",[20],"NOT_YET_RECRUITING","2026-08-26T02:15:03.757872Z","2026-05-05T02:43:28.536530Z",[],[]]